Treatment of systemic hypertension in patients with pulmonary disease: COPD and asthma

Chest

Volumn 123, Issue 1, 2003, Pages 222-243

  Dart, Richard A ^a   Gollub, Steve ^b   Lazar, Jason ^c   Nair, Chandra ^d   Schroeder, David ^e   Woolf, Steven H ^f  

^a MARSHFIELD CLINIC   (United States)

^b UNIVERSITY OF KANSAS MEDICAL CENTER   (United States)

^c WINTHROP UNIVERSITY HOSPITAL   (United States)

^d CREIGHTON UNIVERSITY SCHOOL OF MEDICINE   (United States)

^e Asheville Cardiology Associates   (United States)

^f VIRGINIA COMMONWEALTH UNIVERSITY   (United States)

Author keywords

Antihypertensive drugs; Asthma; COPD; Pulmonary disease; Systemic high BP

Indexed keywords

ANGIOTENSIN 2 RECEPTOR ANTAGONIST; ANTIHYPERTENSIVE AGENT; ATENOLOL; BACLOFEN; BETA ADRENERGIC RECEPTOR BLOCKING AGENT; CALCIUM ANTAGONIST; CELIPROLOL; DIPEPTIDYL CARBOXYPEPTIDASE INHIBITOR; DIURETIC AGENT; HYDROCHLOROTHIAZIDE; LISINOPRIL; LOSARTAN; METOLAZONE; METOPROLOL; NADOLOL; NITRENDIPINE; OXPRENOLOL; PRACTOLOL; PROPRANOLOL; THEOPHYLLINE; VALSARTAN; VERAPAMIL;

ADRENERGIC SYSTEM; ANGIONEUROTIC EDEMA; ANTIHYPERTENSIVE THERAPY; ARTICLE; ASTHMA; BREATHING DISORDER; BRONCHOSPASM; CHRONIC OBSTRUCTIVE LUNG DISEASE; CLINICAL TRIAL; CONGESTIVE HEART FAILURE; COR PULMONALE; COUGHING; DEMOGRAPHY; DRUG ERUPTION; DYSGEUSIA; DYSPNEA; FETUS MALFORMATION; HUMAN; HYPERKALEMIA; HYPERTENSION; HYPOTENSION; INTERSTITIAL PNEUMONIA; KIDNEY FAILURE; LARYNX EDEMA; LUNG DISEASE; NEUTROPENIA; NOSE CONGESTION; PLEURISY; PRIORITY JOURNAL; PROTEINURIA; RENIN ANGIOTENSIN ALDOSTERONE SYSTEM; RHINITIS;

EID: 0037246013     PISSN: 00123692     EISSN: None     Source Type: Journal    
DOI: 10.1378/chest.123.1.222     Document Type: Article

References (131)

1. Dickersin K, Min Y-I, Meinhart CL. Factors influencing publication of research results: follow-up of applications submitted to two institutional review boards. JAMA 1992; 267:374-378
2. Burt VL, Whelton P, Roccella EJ, et al. Prevalence of hypertension in the U.S. adult population: results from the Third National Health and Nutrition Examination survey, 1988-1991. Hypertension 1995; 25:305-313
3. HDFP Cooperative Group. Hypertension detection and follow-up program. Circ Res 1977; 40:1106-1109
4. National Institutes of Health, National Heart, Lung, and Blood Institute. Morbidity and mortality 1996: chartbook on cardiovascular, lung and blood diseases. Bethesda, MD: National Institutes of Health, 1996
5. Benson V, Marano MA. Current estimates from the National Health Interview Survey, 1993. Washington, DC: National Center for Vital and Health Statistics, 1994; 206
6. National Lung Health Education Program Executive Committee. Strategies in preserving lung health and preventing COPD and associated diseases. Chest 1998; 113:123S-159S
7. Adams PF, Marano MA. Current estimates from the National Health Interview Survey, 1994. Vital Health Stat 1995; 10:193
8. Schappert SM. National ambulatory medical care survey: 1994 summary; advance data from vital and health statistics. Hyattsville, MD: National Center for Health Statistics, 1996; 273
9. Burt CW, Knapp DE. Ambulatory care visits for asthma: United States, 1993-1994; advance data from vital and health statistics. Hyattsville, MD: National Center for Health Statistics, 1996; 277
10. Centers for Disease Control. Asthma statistics in the United States from 1982 to 1992. MMWR Morb Mortal Wkly Rep 1995; 43:952-955
11. Evans R, Wilson RW, Rosenberg HM, et al. National trends in the morbidity and mortality of asthma in the U.S.: prevalence, hospitalization and death from asthma over two decades, 1965-1984. Chest 1987; 91:65S-74S
12. Weiss KB, Wagener DK. Changing patterns of asthma mortality: identifying target populations at high risk. JAMA 1990; 264:1683-1687
13. Stewart AL, Greenfield S, Hays RD, et al. Functional status and well-being of patients with chronic conditions: results from the Medical Outcomes Study. JAMA 1989; 262:907-913
14. Adams PF, Benson V. Current estimates from the National Health Interview Survey, 1991. Vital Health Stat 1992; 10:184
15. Hansson L, Zanchetti A, Carruthers SG, et al. The effects of intensive blood pressure lowering and low dose aspirin in patients with hypertension: principal results of the Hypertension Optimal Treatment (HOT) randomised trial. Lancet 1998; 351:1755-1762
16. Sixth Report of the Joint National Committee on Prevention, Detection, Evaluation, and Treatment of High Blood Pressure. Arch Intern Med 1997; 157:2413-2446
17. Staessen JA, Fagard R, Thijs L, et al. Randomised double-blind comparison of placebo and active treatment for older patients with isolated systolic hypertension. The Systolic Hypertension in Europe (SYST-EUR) trial investigators. Lancet 1997; 350:757-764
18. Materson BJ, Reda DJ, Cushman WC, et al, for the Department of Veterans Affairs Cooperative Study on Antihypertensive Agents. Single-drug therapy for hypertension in men: a comparison of six antihypertensive agents with placebo. N Engl J Med 1993; 328:914-921
19. Kannel WB, Hubert H, Lew EA. Vital capacity as a predictor of cardiovascular disease: the Framingham Study. Am Heart J 1983; 105:311-315
20. Higgins M, Keller JB, Wagenknecht LE, et al. Pulmonary function and cardiovascular risk factor relationships in black and in white young men and women: the CARDIA Study. Chest 1991; 99:315-322
21. Tockman MS, Comstock GW. Respiratory risk factors and mortality: longitudinal studies in Washington County. Am Rev Respir Dis 1989; 140:S56-S63
22. Teppeman LJ, Dahan A. Acetazolamide and breathing: does a clinical dose alter peripheral and central CO(2) sensitivity? Am J Respir Crit Care Med 1999; 160:1592-1597
23. Kiwull-Schone HF, Teppema LJ, Kiwull PJ. Low-dose acetazolamide does affect respiratory muscle function in spontaneously breathing anesthetized rabbits. Am J Respir Crit Care Med 2001; 163:478-483
24. Ravn HB, Dorup I. The concentration of sodium, potassium pumps in chronic obstructive lung disease (COLD) patients: the impact of magnesium depletion and steroid treatment. J Intern Med 1997; 241:23-29
25. Pons G, Marchand MC, d'Athis P, et al. French multicenter randomized double-blind placebo-controlled trial on nebulized amiloride in cystic fibrosis patients. Pediatr Pulmonol 2000; 30:25-31
26. Rodriguez Vazquez JC, Pino Alfonso PP, Gassiot Nuno C, et al. Usefulness of inhaled furosemide in a bronchial asthma attack. J Investig Allergol Clin Immunol 1998; 8:290-293
27. Barnes PJ, Wilson NM, Brown MJ. A calcium antagonist, nifedipine, modifies exercise-induced asthma. Thorax 1981; 36:726-730
28. Cerrina J, Denjean A, Alexandre G, et al. Inhibition of exercise-induced asthma by a calcium antagonist, nifedipine. Am Rev Respir Dis 1981; 123:156-160
29. Williams DO, Barnes PJ, Vickers HP, et al. Effect of nifedipine on bronchomotor tone and histamine reactivity in asthma. BMJ 1981; 282:348
30. So SY, Lam WK, Yu DYC. Effect of calcium antagonists on allergen-induced asthma. Clin Allergy 1982; 12:595-600
31. Nair N, Townley RG, Bewtra A, et al. Safety of nifedipine in subjects with bronchial asthma and COPD. Chest 1984; 86:515-518
32. Ahmed T, Russi E, Kim CS, et al. Comparative effects of oral and inhaled verapamil on antigen-induced bronchoconstriction. Chest 1985; 86:176-180
33. Russi EW, Danta I, Ahmed T. Comparative modification of antigen-induced bronchoconstriction by the calcium antagonists nifedipine and verapamil. Chest 1985; 88:74-78
34. Ballester E, Roca J, Rodriguez-Roisin R, et al. Effect of nifedipine on arterial hypoxemia occurring after methacholine challenge in asthma. Thorax 1986; 41:468-472
35. Jackson SH, Shah K, Debbas NM, et al. The interaction between IV theophylline and chronic oral dosing with slow release nifedipine in volunteers. Br J Clin Pharmacol 1986; 21:389-392
36. Schwartzstein RS, Fanta CH. Orally administered nifedipine in chronic stable angina. Am Rev Respir Dis 1986; 134:262-266
37. Smith SR, Wiggins J, Stableforth DE, et al. Effect of nifedipine on serum theophylline concentrations and asthma control. Thorax 1987; 42:794-796
38. Sirmans SM, Pieper JA, Lalonde RL, et al. Effect of calcium channel blockers on theophylline disposition. Clin Pharmacol Ther 1988; 44:29-34
39. Mulloy EM, Cormie P, Harvey J, et al. Nitrendipine therapy in asthmatic subjects. Br J Clin Pharmacol 1990; 30:493-495
40. Kantola I, Rauhala E, Erkinjuntti M, et al. Sleep disturbances in hypertension: a double blind study between isradipine and metoprolol. J Cardiovasc Pharmacol 1991; 18:S41-S45
41. Yilmaz E, Canberk A, Eroglu L. Nifedipine alters serum theophylline levels in asthmatic patients with hypertension. Fundam Clin Pharmacol 1991; 5:341-345
42. Lin M, Yang YF, Lee D, et al. Comparisons of long-term effects of lisinopril vs nifedipine vs conventional therapy in the treatment of mild-to-moderate hypertension in patients with chronic obstructive pulmonary disease. Chinese Med J 1996; 57:392-400
43. Sala H, Abad J, Juanmiquel L, et al. Captopril and bronchial reactivity. Postgrad Med J 1986; 62:76-77
44. Schalekamp M, Dietze G, Bertoli L, et al. Influence of ACE inhibition on pulmonary haemoydynamics and function in patients in whom β-blockers are contraindicated. Postgrad Med J 1986; 62:47-51
45. Riska H, Senius-Aarniala B, Sovijarvi ARA. Comparison of the effects of an angiotensin-converting enzyme inhibitor and a calcium channel blocker on blood pressure and respiratory function in patients with hypertension and asthma. J Cardiovasc Pharmacol 1987; 10(suppl 10):S79-S81
46. Mue S, Tamura G, Yamauchi K, et al. Bronchial responses to enalapril in asthmatic, hypertensive patients. Clin Ther 1990; 12:335-343
47. Kaufman J, Schmitt S, Barnard J, et al. Angiotensin-converting enzyme inhibitors in patients with bronchial responsiveness and asthma. Chest 1992; 101:922-925
48. Lunde H, Hedner T, Samuelsson O, et al. Dyspnoea, asthma, and bronchospasm in relation to treatment with angiotensin converting enzyme inhibitors. BMJ 1994; 308:18-21
49. Wood R. Bronchospasm and cough as adverse reactions to ACE-inhibitors captopril, enalapril and lisinopril: a controlled retrospective cohort study. Br J Clin Pharmacol 1995; 39:265-270
50. Riska H, Sovijarvi ARA, Ahonen A, et al. Effects of captopril on blood pressure and respiratory function compared to verapamil in patients with hypertension and asthma. J Cardiovasc Pharmacol 1990; 15:57-61
51. Kubota K, Kubota N, Pearce G. ACE inhibitor-induced cough, an adverse drug reaction unrecognized for several years: studies in prescription-event monitoring. Eur J Clin Pharmacol 1996; 49:431-437
52. Havelka J, Vetter H, Studer A, et al. Acute and chronic effects of angiotensin-converting enzyme inhibitor captopril in severe hypertension. Am J Cardiol 1982; 49:1467-1474
53. Coulter DM, Edwards IR. Cough associated with captopril and enalapril. BMJ 1987; 194:1521-1523
54. Irvin JD, Viau JM. Safety profiles of the angiotensin-converting enzyme inhibitors captopril and enalapril. Am J Med 1986; 81:46-50
55. Goldszer RC, Lilly LS, Solomon HS. Prevalence of cough during angiotensin converting enzyme inhibitor therapy. Am J Med 1988; 85:887
56. Simon SR, Black HR, Moser M, et al. Cough and ACE inhibitors. Arch Intern Med 1992; 152:1698-1700
57. Folkow B, Johansson B, Mellander S. The comparative effects of angiotensin and noradrenaline on consecutive vascular sections. Acta Physiol Scand 1961; 53:99-104
58. Zimmerman BG, Sybertz EJ, Wong PC. Interaction between sympathetic and renin-angiotensin system. J Hypertens 1984; 2:581-587
59. Padfield PL, Mortone JJ. Effects of angiotensin II on arginine-vasopressin in physiological and pathological situations in man. J Clin Endocrinol 1977; 74:251-259
60. Biron P, Koiw E, Nowaczynski W. The effects of intravenous infusions of valine-5 angiotensin II and other pressor agents on urinary electrolytes and corticoids including aldosterone. J Clin Invest 1961; 60:338-347
61. Regoli D, Barabe J. Pharmacology of bradykinin and related kinins. Pharmacol Rev 1980; 32:1-46
62. Vanhoutte PM. Endothelium and control of vascular function: state of the art lecture. Hypertension 1989; 13:658-667
63. Stein JH, Congbalay RC, Karsh DL, et al. The effect of bradykinin on proximal tubular sodium reabsorption in the dog: evidence for functional nephron heterogeneity. J Clin Invest 1972; 51:1709-1721
64. Proud D, Kaplan AP. Kinin formation: mechanisms and role in inflammatory disorders. Ann Rev Immunol 1988; 6:49-83
65. Skidgel RA, Erdos E. Biochemistry of angiotensin I converting enzyme. In: Robertson JLS, Nicholis MG, eds. The renin-angiotensin system. New York, NY: Raven Press, 1993; 1-10
66. Cohen ML, Kurz KD. Angiotensin converting enzyme inhibition in tissues from spontaneously hypertensive rats after treatment with captopril or MK-421. J Pharmacol Exp Ther 1982; 220:63-69
67. Israili ZH, Hall WD. Cough and angioneurotic edema associated with angiotensin converting enzyme inhibitor therapy: a review of the literature and pathophysiology. Ann Intern Med 1992; 117:234-242
68. Lacourciere Y, Lefebvre J, Nakhle G, et al. Association between cough and angiotensin converting enzyme inhibitors vs angiotensin II antagonists: the design of a prospective, controlled study. J Hypertens 1994; 12:S49-S53
69. Johnson A, Erdos EG. Release of histamine from mast cells by vasoactive peptides. Proc Soc Exp Med Biol 1973; 142:1253-1256
70. Fuller RW, Dixon CMS, Cuss FMC, et al. Bradykinin-induced bronchoconstriction in humans. Am Rev Respir Dis 1987; 135:176-180
71. Ferner RE, Simpson JM, Rawlins MD. Effects of intradermal bradykinin after inhibition of angiotensin converting enzyme. BMJ 1987; 294:1119-1120
72. Varonier HS, Panzani R. Effect of inhalations of bradykinin on healthy and atopic (asthmatic) children. Int Arch Allergy Immunol 1968; 34:293-296
73. Swartz SL. Angiotensin-converting enzyme inhibition and prostaglandins. Am J Cardiol 1982; 49:1405-1409
74. Malini PL, Strocchi E, Zanardi M, et al. Thromboxane antagonism and cough induced by angiotensin-converting-enzyme inhibitor. Lancet 1997; 350:15-18
75. Unemure K, Nakashima M, Saruta T. Thromboxane A2 synthetase inhibition suppresses cough induced by angioten-sin converting enzyme inhibitors. Life Sci 1997; 60:1583-1588
76. Fogari R, Zoppa A, Tettamanti F, et al. Effects of nifedipine and indomethacin on cough induced by angiotensin-converting enzyme inhibitors: a double-blind, randomized, cross-over study. J Cardiovasc Pharmacol 1992; 19:670-673
77. Gilchrist NL, Richards AM, March M, et al. Effects of sulindac on angiotensin converting enzyme inhibitor-induced cough: randomized placebo-controlled double-blind cross-over study. J Human Hypertens 1989; 3:451-455
78. Just PM. The positive association of cough with angiotensin-converting enzyme inhibitors. Pharmacotherapy 1989; 9:82-87
79. Ray NJ, Jones AJ, Keen P, et al. GABA-B receptor modulation of the release of substance P from capsaicin-sensitive neurones in the rat trachea in vitro. Br J Pharmacol 1991; 102:801-804
80. Dicpinigaitis PV, Spungen AM, Bauman WA, et al. Inhibition of bronchial hyperresponsiveness by the GABA-agonist baclofen. Chest 1994; 106:758-761
81. Dicpinigaitis PV. Use of baclofen to suppress cough induced by angiotensin-converting enzyme inhibitors. Ann Pharmacother 1996; 30:1242-1245
82. Semple PF, Herd GW. Cough and wheeze caused by inhibitors of angiotensin-converting enzyme [letter]. N Engl J Med 1986; 314:61
83. Popa V. Captopril-related (and induced?) asthma. Am Rev Respir Dis 1987; 136:999-1000
84. Peacock AJ, Matthews AW. The effect of captopril on pulmonary haemodynamics and lung function in patients with chronic airflow obstruction [abstract]. Thorax 1986; 41:225
85. Witte PU, Irmisch R, Hadju P, et al. Pharmacokinetics and pharmacodynamics of a novel orally active angiotensin converting enzyme inhibitor (HOE 498) in healthy subjects. Eur J Clin Pharmacol 1984; 27:577-581
86. Dixon CMS, Fuller RW, Barnes PJ. The effect of an angiotensin converting enzyme inhibitor, ramipril, on bronchial response to inhaled histamine and bradykinin in asthmatic subjects. Br J Clin Pharmacol 1987; 23:91-93
87. Anderson RG, Karlberg BE, Lindgren BR. Cough and other bronchial symptoms and skin disorders during treatment with ACE inhibitors (Swedish). Lakartidningen 1987; 84: 183-184
88. Fuller RW, Choudry NB. Increased cough reflex associated with angiotensin-converting enzyme inhibitor cough. BMJ 1987; 295:1025-1026
89. Astrom H. Comparison of the effects of airway conductance of a new selective β-adrenergic blocking drug, atenolol, and propranolol in asthmatic patients. Scand J Respir Dis 1975; 56:292-296
90. Formgren H. The effect of metoprolol and practolol on lung function and blood pressure in hypertensive asthmatics. Br J Clin Pharmacol 1976; 3:1007-1014
91. Vilsvik JS, Schaanning J. Effect of atenolol on ventilatory and cardiac function in asthma. BMJ 1976; 2:453-455
92. Christensen CC, Boye, NP, Erickson H, et al. Influence of pindolol (Visken) on respiratory function in 20 asthmatic patients. Eur J Clin Pharmacol 1978; 13:9-12
93. Decalmer PBG, Chatterjee SS, Cruikshank JM, et al. β-Blockers and asthma. Br Heart J 1978; 40:184-189
94. Anderson EG, Calcraft B, Jariwalla AG, et al. Persistent asthma after treatment with β blocking drugs. Br J Dis Chest 1979; 73:407-408
95. Lofdahl C-G, Svedmyr N. Cardioselectivity of atenolol and metoprolol: a study in asthmatic patients. Eur J Respir Dis 1981; 62:396-404
96. Raine JM, Palazzo MG, Kerr JH, et al. Near fatal broncho-spasm after oral nadolol in a young asthmatic and response to ventilation with halothane. BMJ 1981; 282:548-549
97. Ruffin RE, McIntyre ELM, Latimer KM, et al. Assessment of β-adrenoreceptor antagonists in asthmatic patients. Br J Clin Pharmacol 1982; 13:325S-335S
98. Lawrence DS, Sahay JN, Chatterjee SS, et al. β-Blockers in asthma. Drugs 1983; 25:232-236
99. Lammers JWJ, Folgering M, van Herwaarden CLA. Ventilatory effects of long-term treatment with pindolol and metoprolol in hypertensive patients with chronic obstructive lung disease. Br J Clin Pharmacol 1985; 20:205-210
100. Chatterjee SS. The cardioselective and hypotensive effects of bisoprolol in hypertensive asthmatics. J Cardiovasc Pharmacol 1986; 8:S74-S77
101. Dorow P, Bethge H, Tonnesmann U. Effects of single oral doses of bisoprolol and atenolol on airway function in non-asthmatic chronic obstructive lung disease and angina pectoris. Eur J Clin Pharmacol 1986; 31:143-147
102. Dorow P, Clauzel AM, Capone P, et al. A comparison of celiprolol and chlorthalidone in hypertensive patients with reversible bronchial obstruction. J Cardiovasc Pharmacol 1986; 8:S102-S104
103. Doshan HD, Brown R, Applin WJ, et al. Effects of high doses of celiprolol in asthmatic patients. J Cardiovasc Pharmacol 1986; 8:S109-S111
104. Bruschi C, Casali L, Cerveri I, et al. Effects of celiprolol on the bronchial reactivity in asthma. Am J Cardiol 1988; 61:53C-54C
105. Lofdahl C-G, Dahlof C, Westergren G, et al. Controlled-release, metoprolol compared with atenolol in asthmatic patients: interaction with terbutaline. Eur J Clin Pharmacol 1988; 33:S25-32
106. van Zyl AI, Jennings AA, Bateman ED, et al. Comparison of respiratory effects of two cardioselective β-blockers, celiprolol and atenolol, in asthmatics with mild-to-moderate hypertension. Chest 1989; 95:209-213
107. Fogari R, Zoppi A, Tettamanti F, et al. Comparative effects of celiprolol, propranolol, oxprenolol, and atenolol on respiratory function in hypertensive patients with chronic obstructive lung disease. Cardiovasc Drugs Ther 1990; 4:1145-1150
108. Weichler U, Herres-Mayer B, Mayer J, et al. Influence of antihypertensive drug therapy on sleep pattern and sleep apnea activity. Cardiology 1991; 78:124-130
109. Graft DF, Fowles J, McCoy CE, et al. Detection of β-blocker use in people with asthma. Ann Allergy 1992; 69:449-453
110. Bauer K, Kaik G, Kaik B. Osmotic release drug delivery system of metoprolol in hypertensive asthmatic patients: Pharmacodynamic effects on β2-adrenergic receptors. Hypertension 1994; 24:339-346
111. The CONSENSUS Trial Study Group. Effects of enalapril on mortality in severe congestive heart failure: results of the Cooperative North Scandinavian Enalapril Survival Study (CONSENSUS). N Engl J Med 1987; 316:1429-1435
112. The SOLVD Investigators. Effect of enalapril on survival in patients with reduced left ventricular ejection fractions and congestive heart failure. N Engl J Med 1991; 325:293-302
113. Cohn JN, Johnson G, Ziesche J, et al. A comparison of enalapril with hydralazine-isosorbide nitrate in the treatment of chronic congestive heart failure. N Engl J Med 1991; 325:303-310
114. Ravid D, Lishner M, Lang R, et al. Angiotensin-converting enzyme inhibitors and cough: a prospective evaluation in hypertension and congestive heart failure. J Clin Pharmacol 1994; 34:1116-1120
115. Benz J, Oshrain C, Henry D, et al. Valsartan, a new angiotensin II receptor antagonist: a double-blind study comparing the incidence of cough with lisinopril and hydrochlorothiazide. J Clin Pharmacol 1997; 37:101-107
116. Chan P, Tomlinson B, Huang TY, et al. Double-blind comparison of losartan, lisinopril, and metolazone in elderly hypertensive patients with previous angiotensin-converting enzyme inhibitor-induced cough. J Clin Pharmacol 1997; 37:253-257
117. McNeill RS. Effect of a β-adrenergic blocking agent, propranolol, on asthmatics. Lancet 1964; 2:1101-1102
118. Anavekar SN, Barter C, Adam WR, et al. A double-blind comparison of verapamil and labetalol in hypertensive patients with coexisting chronic obstructive airways disease. J Cardiovasc Pharmacol 1982; 4:S374-S377
119. Light RW, Chetty KG, Stansbury DW. Comparison of the effects of labetalol and hydrochlorothiazide on the ventilatory function of hypertensive patients with mild chronic obstructive pulmonary disease. Am J Med 1993; 75:109-114
120. Falliers CJ, Vrchota J, Blasucci DJ, et al. The effects of treatments with labetalol and hydrochlorothiazide on ventilatory function of asthmatic hypertensive patients with demonstrated bronchosensitivity to propranolol. J Clin Hypertens 1985; 1:70-79
121. George RB, Light RW, Hudson LD, et al. Comparison of the effects of labetalol and hydrochlorothiazide on the ventilatory function of hypertensive patients with asthma and propranolol sensitivity. Chest 1985; 88:815-818
122. Anavekar N, Doyle AE. Evaluation of verapamil in the treatment of hypertension. J Clin Hypertens 1986; 3:90S-99S
123. Riska H, Stenius-Aarniala B, Sovijärvi ARA. Comparison of the efficacy of an ACE-inhibitor and a calcium channel blocker in hypertensive asthmatics: a preliminary report. Postgrad Med J 1986; 62(suppl 1):52-53
124. Clauzel AM, Jean T, Etienne R, et al. Effect of long-term treatment with celiprolol on pulmonary function in a group of mild hypertensive asthmatics. J Int Med Res 1988; 16(suppl 1):27A-33A
125. Dorow P. Bronchoneutral effects in hypertensive asthmatics: celiprolol vs chlorthalidone. J Int Med Res 1988; 16(suppl 1):23A-26A
126. Biernacki W, Flenley DC. Doxazosin, a new α-1-antagonist drug, controls hypertension without causing airways obstruction in asthma and COPD. J Hum Hypertens 1989; 3:419-425
127. Chodosh S, Tuck J, Pizzuto D. Prazosin in hypertensive patients with chronic bronchitis and asthma: a brief report. Am J Med 1989; 86(suppl 1B):91-93
128. Mols P, Huynh CH, Dechamps P, et al. Acute effects of nifedipine on systolic and diastolic ventricular function in patients with chronic obstructive pulmonary disease. Chest 1993; 103:1381-1384
129. Cazzola M, Noschese P, D'Amato M, et al. Comparison of the effects of single oral doses of nebivolol and celiprolol on airways in patients with mild asthma. Chest 2000; 118:1322-1326
130. Kraiczi H, Hedner J, Peker Y, et al. Comparison of atenolol, amlodipine, enalapril, hydrochlorothiazide, and losartan for antihypertensive treatment in patients with obstructive sleep apnea. Am J Respir Crit Care Med 2000; 161:1423-1428
131. Tanser PH, Campbell LM, Carranza J, et al. Candesartan cilexetil is not associated with cough in hypertensive patients with enalapril-induced cough. Am J Hypertens 2000; 13: 214-218